Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140
Apogee Therapeutics
Apogee Therapeutics APGE | 0.00 |
Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:
APGE) with a Buy rating and announces Price Target of $140.
